bearish
Viva Biotech (维亚生物) IPO: When CRO Becomes Early Stage Biotech Investor
1.4k Views03 Jan 2019 13:32
Viva Biotechnology, a China-based drug discovery company, is seeking to raise USD 200m to list on the Hong Kong Stock Exchange. In this insight, we...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 9-minute read)
Discussions
(Paid Plans Only)
- ECM Weekly (6 April 2019) - Bilibili, Huya, Qutoutiao, Polycab, PNB Metlife, CIMC Vehicle06 Apr 2019
- ECM Weekly (30 March 2019) - ESR, Yunji, Ruhnn, Jinxin Fertility, Metropolis Health, Viva Biotech30 Mar 2019
- Viva Biotech (维亚生物) IPO: Warning Signs from 2018 Numbers (Part 2)28 Mar 2019
- Viva Biotech (维亚生物) IPO: When CRO Becomes Early Stage Biotech Investor03 Jan 2019
- WuXi Apptec (药明康德) IPO: This A+H Listing Will Be Different20 Nov 2018
- Frontage Holding (方达控股) IPO: More Disclosure Needed to Understand Moat and Growth Prospect05 Nov 2018
x